Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company, will participate in three major investor conferences in September 2025. The company, which is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumor types, will present at:
- Wells Fargo Healthcare Conference (Boston) - September 4, 10:15 AM ET
- H.C. Wainwright Global Investment Conference (New York) - September 8, 2:30 PM ET
- Morgan Stanley Global Healthcare Conference (New York) - September 9, 7:00 AM ET
Live webcasts and recordings will be available on the company's website under the "Events & Presentations" section.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), azienda biofarmaceutica in fase clinica, parteciper脿 a tre importanti conferenze per investitori a settembre 2025. La societ脿, che sta sviluppando un potenziale inibitore WEE1 di prima classe per il trattamento del cancro ovarico e di altri tumori, presenter脿 a:
- Wells Fargo Healthcare Conference (Boston) - 4 settembre, 10:15 ET
- H.C. Wainwright Global Investment Conference (New York) - 8 settembre, 14:30 ET
- Morgan Stanley Global Healthcare Conference (New York) - 9 settembre, 07:00 ET
I webcast in diretta e le registrazioni saranno disponibili sul sito web della societ脿 nella sezione "Events & Presentations".
Zentalis Pharmaceuticals (NASDAQ: ZNTL), una compa帽铆a biofarmac茅utica en etapa cl铆nica, participar谩 en tres conferencias importantes para inversores en septiembre de 2025. La empresa, que est谩 desarrollando un posible inhibidor WEE1 de primera clase para el c谩ncer de ovario y otros tipos de tumor, realizar谩 presentaciones en:
- Wells Fargo Healthcare Conference (Boston) - 4 de septiembre, 10:15 ET
- H.C. Wainwright Global Investment Conference (Nueva York) - 8 de septiembre, 14:30 ET
- Morgan Stanley Global Healthcare Conference (Nueva York) - 9 de septiembre, 07:00 ET
Los webcasts en directo y las grabaciones estar谩n disponibles en la web de la compa帽铆a en la secci贸n "Events & Presentations".
Zentalis Pharmaceuticals (NASDAQ: ZNTL)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿� 2025雲� 9鞗旍棎 臧滌禍霅橂姅 靹� 瓿踌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃╇媹雼�. 雮滌唽鞎� 氚� 旮绊儉 膦呾枒鞚� 鞙勴暅 鞛犾灛鞝� 韻检姢韸胳澑韥措灅鞀� WEE1 鞏奠牅鞝滊ゼ 臧滊皽 欷戩澑 鞚� 須岇偓電� 雼れ潓 頄夓偓鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�:
- Wells Fargo Healthcare Conference (氤挫姢韯�) - 9鞗� 4鞚�, 鞓れ爠 10:15 ET
- H.C. Wainwright Global Investment Conference (雺挫殨) - 9鞗� 8鞚�, 鞓ろ泟 2:30 ET
- Morgan Stanley Global Healthcare Conference (雺挫殨) - 9鞗� 9鞚�, 鞓れ爠 7:00 ET
霛检澊敫� 鞗轨簮鞀ろ姼鞕� 雲鬼檾氤胳潃 須岇偓 鞗轨偓鞚错姼鞚� "Events & Presentations" 靹轨厴鞐愳劀 鞚挫毄頃橃嫟 靾� 鞛堨姷雼堧嫟.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), une soci茅t茅 biopharmaceutique en phase clinique, participera 脿 trois grandes conf茅rences investisseurs en septembre 2025. La soci茅t茅, qui d茅veloppe un inhibiteur WEE1 potentiellement de premi猫re classe pour le cancer de l鈥檕vaire et d鈥檃utres tumeurs, pr茅sentera lors de :
- Wells Fargo Healthcare Conference (Boston) - 4 septembre, 10h15 ET
- H.C. Wainwright Global Investment Conference (New York) - 8 septembre, 14h30 ET
- Morgan Stanley Global Healthcare Conference (New York) - 9 septembre, 07h00 ET
Les webcasts en direct et les enregistrements seront disponibles sur le site web de la soci茅t茅 dans la section "Events & Presentations".
Zentalis Pharmaceuticals (NASDAQ: ZNTL), ein biopharmazeutisches Unternehmen in klinischer Phase, nimmt im September 2025 an drei bedeutenden Investorenkonferenzen teil. Das Unternehmen, das einen potenziellen First鈥慽n鈥慍lass WEE1鈥慖nhibitor f眉r Eierstockkrebs und andere Tumorarten entwickelt, wird pr盲sentieren bei:
- Wells Fargo Healthcare Conference (Boston) 鈥� 4. September, 10:15 ET
- H.C. Wainwright Global Investment Conference (New York) 鈥� 8. September, 14:30 ET
- Morgan Stanley Global Healthcare Conference (New York) 鈥� 9. September, 07:00 ET
Live鈥慦ebcasts und Aufzeichnungen stehen auf der Website des Unternehmens unter der Rubrik "Events & Presentations" zur Verf眉gung.
- None.
- None.
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis庐 Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference, Boston, MA.
- Fireside chat, September 4, 2025, 10:15 a.m. ET.
- H.C. Wainwright 27th Annual Global Investment Conference, New York, NY.
- Company presentation, September 8, 2025, 2:30 p.m. ET.
- Morgan Stanley 23rd Annual Global Healthcare Conference, New York, NY.
- Fireside chat, September 9, 2025, 7:00 a.m. ET.
Access to live webcasts of the events, as well as archived recordings, will be available under the 鈥淓vents & Presentations鈥� tab on the Investors & Media section of the Company鈥檚 .
About Zentalis Pharmaceuticals
Zentalis庐 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN- c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum- resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit Follow Zentalis on LinkedIn at
ZENTALIS庐聽and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
FAQ
When is Zentalis presenting at the Wells Fargo Healthcare Conference 2025?
What type of drug is Zentalis (ZNTL) developing?
How can investors access Zentalis (ZNTL) conference presentations in September 2025?
Which investor conferences is Zentalis (ZNTL) attending in September 2025?
